Invitrogen™ CD42b Monoclonal Antibody (HIP1), eBioscience™, Invitrogen™

Description

Description: The HIP1 monoclonal antibody reacts with the human CD42b molecule, a 135 kDa transmembrane protein also known as platelet gpIb. Applications Reported: The HIP1 antibody has been reported for use in flow cytometric analysis, in vitro blocking of human CD42b, immunoblotting (WB), and immunohistochemical staining. (Please use Functional Grade purified HIP1, cat. 16-0429, in functional assays.). Applications Tested: The HIP1 antibody has been tested by flow cytometric analysis of human platelets and can be used less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibodies be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD42b is a platelet activation marker involved in the process of coagulation as an aggregating factor. It interacts with extracellular matrix as well as with adhesion molecules. CD42b expression and activation seems to be regulated by VEGF and PDGF. CD42b composes together with GPIb beta, GPIX and GPV the GPIb-IX-V receptor complex critical in the process of platelet-rich thrombus formation by tethering the platelet to a thrombogenic surface. CD42b binds to von Willebrand factor (VWF) exposed at a site of vascular injury, as well as to thrombin, coagulation factors XI and XII, high molecular wight kininogen, TSP-1, integrin Mac-1 and P-selectin. The extracellular domain of CD42b by its interactions also contributes to metastasis. Further, CD42b antigen is expressed on platelets and on megakaryocytes in bone marrow. Several polymorphisms and mutations have been described in the CD42b, some of which are the cause of Bernard-Soulier syndromes and platelet-type von Willebrand disease.